Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
Part of paid clinical trials in Huntsville, Alabama.
- Sponsor
- University of Louisville
- Study ID
- NCT00932438
- Phase
- PHASE1/PHASE2
- Status
- Completed
Conditions
- Colon Cancer With Metastases to the Liver
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- LC beads loaded with Irinotecan — DEVICEChemoembolization using LC beads loaded with 100mg Irinotecan
- Oxaliplatin — DRUGOxaliplatin 85 mg/sqm, IV infusion every two weeks
- Leucovorin — DRUGLeucovorin 200 mg/sqm, IV infusion every two weeks
- 5-Fluorouracil — DRUG5-Fluorouracil 2400 mg/sqm, IV infusion every 2 week
- Bevacizumab — DRUGBevacizumab 5 mg/kg given at the discretion of the treating physician
Study Details
This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in patients with colorectal cancer.
Key Dates
- First listed
- Jul 3, 2009
- Start date
- Jun 30, 2009
- Status verified
- Mar 2018
- Primary completion
- Dec 31, 2012
- Completion
- Dec 31, 2012
Study Design
- Enrollment
- 70 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: LC Beads loaded with Irinotecan and FOLFOX6Device: LC Beads loaded with 100mg Irinotecan Drug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
- Active Comparator: FOLFOX6 and BevacizumabDrug: Systemic Chemotherapy (FOLFOX6) Oxaliplatin 85 mg/sqm, IV infusion every two weeks Leucovorin 200mg/sqm, IV infusion every two weeks 5-Fluorouracil 2400mg/sqm, IV infusion every two weeks Bevacizumab 5mg/kg given at the discretion of treating physician
Primary Outcome Measure
Tumor Response [ Time Frame: Months 2, 4 and 6 ]
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Clearview Cancer Center | Huntsville | Alabama | 35805 | - |
| Radiology Associates of Sacramento/Sutter Cancer Center | Sacramento | California | 95816 | - |
| Emory University | Atlanta | Georgia | 30322 | - |
| Northside Hospital/GA Cancer Specialists | Atlanta | Georgia | 30342 | - |
| University of Louisville | Louisville | Kentucky | 40202 | - |
| Hematology and Oncology Assoc. at Bridgeport | Tupelo | Mississippi | 38801 | - |
| Washington University/Alvin J. Siteman Cancer Center | St Louis | Missouri | 63110 | - |
| Providence Portland Medical Center/Providence Cancer Center | Portland | Oregon | 97213 | - |
| Froedtert Memorial Lutheran Hospital | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Huntsville, AL
By research site